Anna Kalisz

Anna Kalisz is an experienced clinical project manager with a strong background in clinical trial management within the biopharmaceutical industry. Currently serving as Study Project Manager I at ImmunoGen, Inc. since November 2022, Anna leads global efforts on the Phase 3 Registrational trial Gloriosa. Previously, Anna held positions such as Senior Clinical Trial Manager at Rain Therapeutics and BeiGene, overseeing significant projects including the global lead for the SARS-CoV-2 Neutralizing Antibody BGB-DXP593. Additional experience includes roles at Retrophin, Boston Biomedical Associates, Dana-Farber Cancer Institute, UMass Medical School, and Fitchburg State University. Anna holds a Bachelor of Science degree in Biology and Chemistry from Worcester State University.